VolitionRX (NYSEAMERICAN:VNRX) Given a $5.00 Price Target by Oppenheimer Analysts

Oppenheimer set a $5.00 target price on VolitionRX (NYSEAMERICAN:VNRX) in a report published on Friday, November 9th. The brokerage currently has a buy rating on the medical research company’s stock.

NYSEAMERICAN:VNRX traded up $0.05 on Friday, hitting $2.29. 40,500 shares of the company’s stock traded hands, compared to its average volume of 105,591. VolitionRX has a 1 year low of $1.44 and a 1 year high of $4.00.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Wednesday, November 7th. The medical research company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14).

A hedge fund recently raised its stake in VolitionRX stock. Bridgeway Capital Management Inc. increased its stake in VolitionRX Ltd (NYSEAMERICAN:VNRX) by 12.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 224,400 shares of the medical research company’s stock after purchasing an additional 25,000 shares during the quarter. Bridgeway Capital Management Inc. owned approximately 0.64% of VolitionRX worth $581,000 at the end of the most recent reporting period.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Recommended Story: NASDAQ

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply